Teachers Retirement System of The State of Kentucky lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 24.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 100,850 shares of the company’s stock after selling 32,660 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Novo Nordisk A/S were worth $3,823,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Financial Freedom LLC acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $30,000. Continuum Advisory LLC acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $38,000. Root Financial Partners LLC acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $32,000. Markowski Investments acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at about $43,000. Finally, Latitude Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the third quarter valued at about $38,000. Institutional investors and hedge funds own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Down 3.0%
Shares of NVO opened at $39.49 on Thursday. The firm has a market cap of $176.32 billion, a P/E ratio of 9.95, a price-to-earnings-growth ratio of 1.40 and a beta of 0.70. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $64.16. The company’s 50-day moving average price is $39.79 and its 200 day moving average price is $43.05. The company has a current ratio of 0.84, a quick ratio of 0.64 and a debt-to-equity ratio of 0.54.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the stock. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Thursday, September 10th. UBS Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Thursday, August 6th. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Friday, October 9th. Five analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $59.44.
Read Our Latest Report on Novo Nordisk A/S
Recent Novo Nordisk A/S Headlines
Here are a few of the latest headlines about NVO:
- Positive Sentiment: Novo’s redesigned NovoCare program combines Wegovy access and home delivery with an app and patient support. It could help the company engage and retain patients, though the announcement did not quantify any expected sales impact. Article: Novo launches the new Novocare
- Neutral Sentiment: Novo and nference are collaborating on research into cardiometabolic disease and healthy ageing. The partnership may support future research, but no specific drug, timeline, or financial contribution was reported. Article: nference and Novo partner
- Negative Sentiment: Comparisons with Eli Lilly underscore competitive pressure: Lilly has delivered strong growth from its metabolic and weight-loss portfolio, while Novo’s established global reach is a counterpoint rather than evidence that the gap is closing. Article: Eli Lilly vs. Novo Nordisk
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
